Relay Therapeutics Leaps as Zovegalisib Shows Promise in Rare Vascular Anomalies
Relay Therapeutics Inc. (NASDAQ: RLAY) is jumping after the company reported encouraging initial data from its Phase 2 ReInspire trial of zovegalisib (RLY‑2608) in patients with rare, PIK3CA‑driven vascular anomalies. The update reinforces the idea that RLAY’s lead PI3Kα inhibitor could have meaningful potential beyond breast cancer, in a high‑need genetic disease segment.
What Relay Therapeutics reported
Relay Therapeutics said early results from its Phase 2 ReInspire trial (NCT06789913) showed that zovegalisib produced promising lesion shrinkage in adults and children with PIK3CA‑related overgrowth spectrum (PROS) and other PIK3CA‑driven vascular malformations. According to the company, zovegalisib achieved a 60% volumetric response rate across all doses and around 29% at the lowest tested 100mg twice‑daily dose, while maintaining a tolerable safety profile.
These data are being presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, giving the story visibility with specialists who manage these complex, often debilitating conditions.
Why the stock moved
Shares of Relay Therapeutics climbed roughly 15% intraday after the Investing.com report highlighted the positive ReInspire data and expanding opportunity for zovegalisib. Investors are responding to the potential of a second major value pillar for the drug, on top of its ongoing development in HR+/HER2‑ metastatic breast cancer in the ReDiscover and ReDiscover‑2 programs.
The company has previously rallied on zovegalisib news, including a move of more than 30% when it first spotlighted the vascular anomalies program, so today’s surge continues that pattern of data‑driven upside.
Investor lens on RLAY
For investors, the ReInspire data strengthen the “platform” case for zovegalisib: one molecule with potential across both oncology and rare vascular diseases. Key watchpoints now include durability of responses, longer safety follow‑up, regulatory feedback on the vascular anomaly pathway, and progress in the larger breast cancer trials.
